Terugbetaling levensnoodzakelijke medicatie / Remboursement

Guido

/ #1234 Info over "arm" bedrijf:

2013-05-02 12:11

Cijfers en contact gegevens van dit "arm" bedrijf: (revenue in 2011: US$ 783.431 million (2011)45%)

Alexion Pharmaceuticals
Type Public
Traded as
NASDAQ: ALXN
NASDAQ-100 component

S&P 500 Component
Industry Pharmaceutical
Founded 1992
Headquarters Cheshire, Connecticut, U.S.
Key people Max E. Link (Chairman)
Leonard Bell (CEO)
Products Eculizumab
Revenue US$ 783.431 million (2011)45%[1]
Operating income US$ 230.826 million (2011)53%[1]
Net income US$ 175.315 million (2011)81%[1]
Total assets US$ 1.395 billion (2011)38%[1]
Total equity US$ 1.134 billion (2011)32%[1]
Employees 792 (December 2010)[1]
Website alxn.com

Media Contacts
Irving Adler
Exec. Director, Corporate Communications
203-272-2596
AdlerI@alxn.com

Kim Diamond
Director, Corporate Communications
203-439-9600
DiamondK@alxn.com